Dupixent
-
Dupixent® (dupilumab) Outperforms Xolair® (omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Patients with Asthma: First-of-its-Kind Phase 4 Head-to-Head Respiratory Trial
The EVEREST Phase 4 trial presented at the 2025 EAACI conference demonstrated that Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and asthma. The study showed superior results for Dupixent across all endpoints for both conditions, including nasal polyp size reduction, improved smell, and enhanced lung function. This head-to-head comparison represents a significant milestone in respiratory disease treatment.
-
Dupixent® (dupilumab) Data at RAD Conference Strengthens Position in Atopic Dermatitis Treatment for Patients of Color
Regeneron and Sanofi announced positive Phase 4 trial results for Dupixent in treating moderate-to-severe atopic dermatitis in adults and adolescents with skin of color. The DISCOVER trial, involving 120 patients, showed significant improvements in disease severity, itch reduction, and post-inflammatory hyperpigmentation. The safety profile aligned with previous findings. This marks a significant advancement in treating this often-underserved population.
